|
Can This Small-Cap Triple?
Barron’s A treatment it tested as an asthma remedy showed some encouraging signs, but the same drug, TC-6987, came up short of its end targets as a diabetes treatment; the pursuit of TC-6987 as a diabetes cure has been terminated, though Targacept is continuing … Targacept (TRGT) Can Fail and Yet Still Win for Investors – Barron's |
View full post on asthma – Google News